Biw-8962
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma
Kyowa Kirin Korea Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Biw-8962 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →